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The median age at diagnosis of Chronic Myeloid 
Leukemia (CML) reported in clinical trials is generally 
of 50-55 years; it is higher (more than 60 years) in 
epidemiologic registries and in observational studies 
[1]. Therefore, a significant proportion of CML patients 
are “elderly”, according to the most widely accepted 
definition of “old person” (age > 65 years).  
 
Prior to imatinib (IM) introduction, an orally taken 
tyrosine kinase inhibitor, older age was associated to a 
worse outcome (lower response rates and lower long-
term survival), regardless of the treatment used 
(busulfan, hydroxyurea, interferon alpha), basically, for 
unknown reasons. It can be speculated that, with 
interferon, the reason of an inferior outcome of elderly 
patients lied in a poorer compliance; however, this 
worsen prognosis of elderly CML patients have been 
described even employing well tolerated drugs (like 
hydroxyurea).   Age was included in the 2 most used 
risk scores for CML: Sokal score (1984), referring to 
patients treated with conventional chemotherapy, and 
EURO score (1998), for patients treated with interferon 
[2,3].
  
 
The introduction of IM has revolutionized the therapy of 
CML patients, significantly improving survival [4]. 
However, in the early days of IM, many physicians felt 
that the prognosis of an old CML patient, particularly 
those older than 75-80 yrs, could not be positively 
influenced by IM and a not negligible part of elderly 
patients are still not allocated to IM (or enrolled in 
clinical trials) for different reasons (co-morbidities, 
toxicity, long term outcome, socio-economic factors) [5].  
 
The importance of age in the IM era has been 
investigated in different studies, leading to a re-
evaluation of its prognostic significance. A large study 
in late chronic phase patients treated with IM after 
interferon failure, conducted by GIMEMA (Gruppo 
Italiano Malattie Ematologiche dell’Adulto) CML 
Working-Party (WP), showed lower hematologic and 
cytogenetic response rates in older patients (> 65 years 
old), but similar overall survival with a 36 months 
median follow-up [6].
  In another large but 
heterogeneous (early chronic phase, late chronic phase, 
and advanced phases) series of patients treated with  IM  
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at the MDACC, older age appeared to be not associated 
with a worse outcome; however, the cut-off to define 
older patients was 60 years, elderly early chronic phase 
patients were few (49) and no long term data were 
available [7].  
 
The first study to evaluate the effect of age in large 
series of front-line IM treated patients and with a long 
follow-up was recently published by the GIMEMA 
CML WP [8]. Five hundred and fifty nine patients, of 
whom 115 ≥ 65 years old, were enrolled in 3 
prospective, multicenter, trials. After a median follow-
up of 60 months, hematologic, cytogenetic and 
molecular response rates were identical in older and 
younger patients while survival was significantly 
inferior in older patients. This lower survival was due to 
a higher number of deaths occurred in chronic phase, 
reasonably unrelated to IM therapy or toxicity, and not 
to a higher progression rate in older patients. 
 
Recently a new prognostic score was elaborated based 
on 2060 patients enrolled in studies of first-line IM-
based regimes and collected by the European Leukemia 
Net / EUTOS Registry [9]. Of the all variables 
analyzed, only spleen size and basophils percentage, 
best discriminated between high-risk and low-risk 
patients; age had no more a prognostic impact, a further 
confirmation that IM has cancelled the differences in 
prognosis between younger and older patients. 
 
No doubt, the overall toxicity and the need for dose 
optimization are higher for IM with respect to 
conservative and palliative treatments, like 
hydroxyurea, particularly when older patients are 
treated; however, in the hands of expert physicians IM 
is generally manageable. Moreover, as the lower 
survival of elderly patients is mainly determined by age-
related factors and co-morbidities, rather than by the 
progression of CML, a geriatric assessment (frailty 
status) may be helpful in the decision to allocate 
selected patients to IM therapy [10]. 
 
In conclusion, age had relevance when therapeutic 
strategies, like IM, were not available. However, today, 
older age per se must not be a limitation for treating 
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clinical trials should be encouraged. 
 
Second generation tyrosine kinase inhibitors (dasatinib 
and nilotinib) as front-line therapy showed higher 
response rates and lower toxicities compared to IM 
[11,12]; probably these results will be confirmed also in 
elderly patients. Importantly, extra-hematologic 
toxicities are distinct between IM, dasatinib and 
nilotinib, allowing the selection of the more appropriate 
drug in relation to the presence of co-morbidities. 
Although data on dasatinib and nilotinib in elderly 
patients are still few and the follow-up is still short, 
these second generation tyrosine kinase inhibitors will 
probably further improve the outcome of CML elderly 
patients. 
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